Detail
Article
Online article
FT
Medvik - BMC
  • Something wrong with this record ?

ATG5 as biomarker for early detection of malignant mesothelioma

M. Tomasetti, F. Monaco, O. Strogovets, L. Volpini, M. Valentino, M. Amati, J. Neuzil, L. Santarelli

. 2023 ; 16 (1) : 61. [pub] 20230424

Language English Country England, Great Britain

Document type Journal Article

Persistent link   https://www.medvik.cz/link/bmc23011720

OBJECTIVES: Malignant pleural mesothelioma (MPM) is an aggressive disease with grim prognosis due to lack of effective treatment options. Disease prediction in association with early diagnosis may both contribute to improved MPM survival. Inflammation and autophagy are two processes associated with asbestos-induced transformation. We evaluated the level of two autophagic factors ATG5 and HMGB1, microRNAs (miRNAs) such as miR-126 and miR-222, and the specific biomarker of MPM, soluble mesothelin related proteins (Mesothelin) in asbestos-exposed individuals, MPM patients, and healthy subjects. The performance of these markers in detecting MPM was investigated in pre-diagnostic samples of asbestos-subjects who developed MPM during the follow-up and compared for the three groups. RESULTS: The ATG5 best distinguished the asbestos-exposed subjects with and without MPM, while miR-126 and Mesothelin were found as a significant prognostic biomarker for MPM. ATG5 has been identified as an asbestos-related biomarker that can help to detect MPM with high sensitivity and specificity in pre-diagnostic samples for up to two years before diagnosis. To utilize this approach practically, higher number of cases has to be tested in order to give the combination of the two markers sufficient statistical power. Performance of the biomarkers should be confirmed by testing their combination in an independent cohort with pre-diagnostic samples.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc23011720
003      
CZ-PrNML
005      
20230801133256.0
007      
ta
008      
230718s2023 enk f 000 0|eng||
009      
AR
024    7_
$a 10.1186/s13104-023-06330-1 $2 doi
035    __
$a (PubMed)37095543
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a enk
100    1_
$a Tomasetti, Marco $u Department of Clinical and Molecular Sciences, Polytechnic University of Marche, Via Tronto 10A, Ancona, 60126, Italy. m.tomasetti@univpm.it
245    10
$a ATG5 as biomarker for early detection of malignant mesothelioma / $c M. Tomasetti, F. Monaco, O. Strogovets, L. Volpini, M. Valentino, M. Amati, J. Neuzil, L. Santarelli
520    9_
$a OBJECTIVES: Malignant pleural mesothelioma (MPM) is an aggressive disease with grim prognosis due to lack of effective treatment options. Disease prediction in association with early diagnosis may both contribute to improved MPM survival. Inflammation and autophagy are two processes associated with asbestos-induced transformation. We evaluated the level of two autophagic factors ATG5 and HMGB1, microRNAs (miRNAs) such as miR-126 and miR-222, and the specific biomarker of MPM, soluble mesothelin related proteins (Mesothelin) in asbestos-exposed individuals, MPM patients, and healthy subjects. The performance of these markers in detecting MPM was investigated in pre-diagnostic samples of asbestos-subjects who developed MPM during the follow-up and compared for the three groups. RESULTS: The ATG5 best distinguished the asbestos-exposed subjects with and without MPM, while miR-126 and Mesothelin were found as a significant prognostic biomarker for MPM. ATG5 has been identified as an asbestos-related biomarker that can help to detect MPM with high sensitivity and specificity in pre-diagnostic samples for up to two years before diagnosis. To utilize this approach practically, higher number of cases has to be tested in order to give the combination of the two markers sufficient statistical power. Performance of the biomarkers should be confirmed by testing their combination in an independent cohort with pre-diagnostic samples.
650    _2
$a lidé $7 D006801
650    12
$a maligní mezoteliom $7 D000086002
650    _2
$a mezotelin $7 D000090204
650    12
$a mezoteliom $x diagnóza $7 D008654
650    _2
$a GPI-vázané proteiny $x škodlivé účinky $7 D058851
650    12
$a nádory pleury $x diagnóza $7 D010997
650    _2
$a nádorové biomarkery $x metabolismus $7 D014408
650    12
$a azbest $x škodlivé účinky $7 D001194
650    12
$a mikro RNA $7 D035683
650    _2
$a časná diagnóza $7 D042241
650    12
$a nádory plic $x diagnóza $7 D008175
650    _2
$a Atg5 $7 D000071187
655    _2
$a časopisecké články $7 D016428
700    1_
$a Monaco, Federica $u Department of Excellence SBSP-Biomedical Sciences and Public Health, Polytechnic University of Marche, Via Tronto 10A, Ancona, 60126, Italy
700    1_
$a Strogovets, Olga $u Department of Clinical and Molecular Sciences, Polytechnic University of Marche, Via Tronto 10A, Ancona, 60126, Italy
700    1_
$a Volpini, Luca $u Department of Clinical and Molecular Sciences, Polytechnic University of Marche, Via Tronto 10A, Ancona, 60126, Italy
700    1_
$a Valentino, Matteo $u Department of Clinical and Molecular Sciences, Polytechnic University of Marche, Via Tronto 10A, Ancona, 60126, Italy
700    1_
$a Amati, Monica $u Department of Clinical and Molecular Sciences, Polytechnic University of Marche, Via Tronto 10A, Ancona, 60126, Italy
700    1_
$a Neuzil, Jiri $u Mitochondria, Apoptosis and Cancer Research Group, School of Pharmacy and Medical Science, Griffith University, Southport, Qld, 4222, Australia $u Molecular Therapy Group, Institute of Biotechnology, Czech Academy of Sciences, Prague- West, 252 50, Czech Republic $u Faculty of Science and First Faculty of Medicine, Charles University, Prague 2, 128 00, Czech Republic
700    1_
$a Santarelli, Lory $u Department of Clinical and Molecular Sciences, Polytechnic University of Marche, Via Tronto 10A, Ancona, 60126, Italy
773    0_
$w MED00165970 $t BMC research notes $x 1756-0500 $g Roč. 16, č. 1 (2023), s. 61
856    41
$u https://pubmed.ncbi.nlm.nih.gov/37095543 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20230718 $b ABA008
991    __
$a 20230801133253 $b ABA008
999    __
$a ok $b bmc $g 1963889 $s 1197985
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2023 $b 16 $c 1 $d 61 $e 20230424 $i 1756-0500 $m BMC research notes $n BMC Res Notes $x MED00165970
LZP    __
$a Pubmed-20230718

Find record

Citation metrics

Archiving options